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Stability of High-Quality Warfarin Anticoagulation in a
Community-Based Atrial Fibrillation Cohort: The Anticoagulation and
Risk Factors in Atrial Fibrillation (ATRIA) Study
Liane O. Dallalzadeh, BS; Alan S. Go, MD; Yuchiao Chang, PhD; Leila H. Borowsky, MPH; Margaret C. Fang, MD, MPH; Daniel E. Singer, MD
Background-—Warfarin reduces ischemic stroke risk in atrial ﬁbrillation (AF) but increases bleeding risk. Novel anticoagulants
challenge warfarin as stroke-preventive therapy for AF. They are available at ﬁxed doses but are more costly. Warfarin
anticoagulation at a time in therapeutic range (TTR) ≥70% is similarly as effective and safe as novel anticoagulants. It is unclear
whether AF patients with TTR ≥70% will remain stably anticoagulated and avoid the need to switch to a novel anticoagulant. We
assessed stability of warfarin anticoagulation in AF patients with an initial TTR ≥70%.
Methods and Results-—Within the community-based Anticoagulation and Risk Factors in AF (ATRIA) cohort followed from 1996 to
2003, we identiﬁed 2841 new warfarin users who continued warfarin over 9 months. We excluded months 1 to 3 to achieve a
stable dose. For the 987 patients with TTR ≥70% in an initial 6-month period (TTR1; months 4–9), we described the distribution of
TTR2 (months 10–15) and assessed multivariable correlates of persistent TTR ≥70%. Of patients with TTR1 ≥70%, 57% persisted
with TTR2 ≥70% and 16% deteriorated to TTR2 <50%. Only initial TTR1 ≥90% (adjusted odds ratio 1.47, 95% CI 1.07–2.01)
independently predicted TTR2 ≥70%. Heart failure was moderately associated with marked deterioration (TTR2 <50%); adjusted
odds ratio 1.45, 95% CI 1.00–2.10.
Conclusions-—Nearly 60% of AF patients with high-quality TTR1 on warfarin maintained TTR ≥70% over the next 6 months.
A minority deteriorated to very poor TTR. Patient features did not strongly predict TTR in the second 6-month period. Our analyses
support watchful waiting for AF patients with initial high-quality warfarin anticoagulation before considering alternative
anticoagulants. ( J Am Heart Assoc. 2016;5:e003482 doi: 10.1161/JAHA.116.003482)
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A trial ﬁbrillation (AF) is the most frequent signiﬁcantcardiac arrhythmia and the strongest common risk
factor for ischemic stroke.1 It increases stroke risk 5-fold and
accounts for 15% of all strokes in the United States.2,3
Moreover, strokes caused by AF are more likely to prove fatal
or severely disabling.4,5 High-quality anticoagulant therapy
can largely prevent AF-associated thromboembolic events
while minimizing bleeding risk.6 AF patients taking warfarin
are at the lowest risk for both thromboembolism and
intracranial hemorrhage at International Normalized Ratio
(INR) levels of 1.8 to 3.5, a range that includes the guideline-
recommended range of 2.0 to 3.0.7,8 Frequent INR monitoring
with dose adjustment is generally needed to maintain INR
levels in this target range of 2.0 to 3.0.9 Recently developed
novel anticoagulants (ie, dabigatran, rivaroxaban, apixaban,
and edoxaban) now compete with warfarin as the primary
stroke-preventive therapy for AF patients. These agents offer
ﬁxed oral doses without the need for frequent INR monitoring
and with a reduced risk of intracranial hemorrhage compared
with average to poor warfarin anticoagulation control.10 These
novel agents appear to be particularly attractive for AF
patients starting anticoagulant therapy. What remains unclear
is whether AF patients who are well anticoagulated on
warfarin should switch to a novel agent.
Time in the therapeutic range (TTR) of INR 2.0 to 3.0 is the
standard means of assessing quality of warfarin therapy.11
Secondary analyses of randomized trials indicate that warfarin
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at TTR ≥70% has efﬁcacy and safety comparable to novel
anticoagulants, suggesting that patients with TTR ≥70% would
gain little clinical beneﬁt from switching to a novel anticoag-
ulant.12–14 This assumes, however, that such a high TTR is
stable over time. Limited analyses have examined the stability
of TTR in AF patients taking warfarin over a prolonged
period.15–17 Our study aimed to address this knowledge gap
by assessing the stability of high-quality anticoagulation over
12 months among patients initiating warfarin. Speciﬁcally, we
used a large, real-world cohort of AF patients newly taking
warfarin to determine the percentage of patients with an
initial 6-month TTR (TTR1) ≥70% whose TTR persisted at ≥70%
in the subsequent 6-month period (TTR2). We then assessed
patient features potentially predicting continued high-quality
TTR. Addressing these aims can provide guidance to patients
and their providers when making the decision to continue
warfarin or to switch to a novel agent.
Methods
Cohort Assembly
The Anticoagulation and Risk Factors in Atrial Fibrillation
(ATRIA) cohort consists of 13 559 adults diagnosed with
nonvalvular AF who received care at Kaiser Permanente
Northern California, a large integrated health care delivery
system. Details of cohort identiﬁcation have been described
previously.18 Brieﬂy, patients were identiﬁed between July 1,
1996, and December 31, 1997, by searching outpatient
databases in which an International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation diagnosis of AF (427.31)
was assigned and by searching electrocardiographic databases
for diagnoses of AF. Those with at least 1 outpatient diagnosis
of AF and an ECG diagnosis of AF were included in the cohort.
Index date was deﬁned as the date of ﬁrst diagnosis of AF
during cohort assembly. Patients were followed until Septem-
ber 30, 2003 (median 6.0 years; interquartile range 3.1–
6.7 years), and censored at death or disenrollment from the
health plan. Exclusion criteria included patients with diagnoses
of mitral stenosis, valvular repair or replacement, transient
postoperative AF, or concurrent hyperthyroidism to limit the
cohort to those with nontransient, nonvalvular AF.
The study was approved by the institutional review boards
of the collaborating institutions. Waiver of informed consent
was obtained due to the nature of the study.
Study Variables
Our analysis focused exclusively on AF patients who were new
and continuous users of warfarin. Warfarin status was assessed
Figure 1. Selection of study cohort. Of the 13 559 patients in the ATRIA AF cohort, 4460 met the criteria for
new starts on warfarin during the study period. Of these, 2928 had ≥9 months of continuous warfarin use,
including our initial 3-month dose-ﬁnding period and our ﬁrst period assessing TTR (months 4–9). There were
2841 patients who had interpolatable INR values (ie, calculable TTR values) in period 1. From these, we identiﬁed
the1156patients newly startedonwarfarin andwhohad a TTR≥70% in period 1 (TTR1,months4–9). The primary
analysis focused on the 987 patients who had TTR1 ≥70% and had a calculable TTR in period 2 (TTR2, months
10–15). In a sensitivity analysis, we also included the 58 patients with TTR1 ≥70% who discontinued warfarin in
period2.Wedid not include the following categories of patients in the analysis of TTR2: (1) died inperiod2 (n=16),
(2) discontinued warfarin in period 2 but restarted warfarin within 1 year (n=42), (3) period 2 follow-up was
incomplete because the study ended (n=33), (4) no interpolatable INR values in period 2 (n=17), and (5)
disenrolled in the health plan during period 2 (n=3). AF indicates atrial ﬁbrillation; ATRIA, anticoagulation and risk
factors in atrial ﬁbrillation; INR, International Normalized Ratio; TTR, time in the therapeutic range.
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based on dispensed warfarin prescriptions and outpatient INR
values in automated pharmacy and laboratory databases and
was validated against warfarin status documented in medical
records of potential outcome events.19 New users were deﬁned
as patients with a new prescription for warfarin during the
cohort assembly period who had no prior identiﬁed warfarin
prescription and <2 outpatient INR measurements in the
previous 12 months.19 Continuous warfarin exposure was
deﬁned as periods of <60 days between the end of the days
supplied and the beginning of the subsequent prescription for
any 2 consecutive ﬁlled prescriptions. For periods >60 days,
continuous warfarin use was assumed if there were intervening
INR measurements at least every 42 days. If neither require-
ment was met, the patient was considered to have discontin-
ued warfarin from day 31 after the end date of the ﬁrst
prescription until the start date of the next prescription. The
30-day grace period was provided to account for reductions in
dose or skipped doses.
TTR is the percentage of time an AF patient maintains an INR
between 2.0 and 3.0. Using each patient’s INR data, we
calculated individual patient TTRs via the standard Rosendaal
interpolation method for both an initial 6-month period and the
subsequent 6-month period.20 This method deﬁnes TTR as the
number of person-days with an INR between 2.0 and 3.0
divided by total number of person-days for which INR could be
interpolated. It assumes that changes between consecutive
INRmeasurements are linear over time. We also provided a TTR
for the INR range 1.8 to 3.5; there is empirical evidence that
this is the full optimal INR range.7 Our 12-month study period
excluded the ﬁrst 3 months of warfarin use; this is a “break-in”
period during which optimal warfarin dosing is sought. The
initial period was deﬁned as months 4 to 9 inclusive, providing
our measures of TTR1, and the subsequent period was deﬁned
as months 10 to 15 inclusive, providing TTR2. We excluded the
8.1% of time on warfarin during which the inter-INR interval was
>8 weeks.21 Characteristics of patients with and without
9 months of continuous warfarin use following initial prescrip-
tion are shown for reference in Table S1.
Covariates included demographic features, risk factors for
stroke in patients with AF, the CHA2DS2-VASc and ATRIA stroke
risk scores, a current or past diagnosis of cancer (excluding
nonmelanoma skin cancer), and common rate and rhythm
control drugs used in AF. Covariates were identiﬁed using
Table 1. Features of ATRIA Cohort Patients Initiating
Warfarin Therapy and Continuing to Take Warfarin Therapy for
at Least 9 Months
Variable* All Patients, n (%)
All 2841 (100)
Age
<75 y 1614 (56.8)
≥75 y 1227 (43.2)
Sex
Men 1597 (56.2)
Women 1244 (43.8)
Race
White 2478 (87.2)
Other 363 (12.8)
Diabetes mellitus 466 (16.4)
Hypertension 1575 (55.4)
Coronary heart disease 797 (28.1)
Heart failure 752 (26.5)
Peripheral artery disease 71 (2.5)
Renal impairment† 351 (12.4)
Prior stroke 262 (9.2)
Cancer 337 (11.9)
Prior bleed 154 (5.4)
Beta blockers 945 (33.3)
Antiarrhythmics 469 (16.5)
Calcium channel blockers 744 (26.2)
ATRIA stroke risk score at admission‡
0–5 1455 (51.2)
6 404 (14.2)
≥7 982 (34.6)
CHA2DS2-VASc score at admission
§
0 161 (5.7)
1 439 (15.5)
≥2 2241 (78.9)
ATRIA indicates anticoagulation and risk factors in atrial ﬁbrillation; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease.
*Variables assessed at the beginning of the 15-month follow-up period.
†eGFR <45 mL/min/1.73 m2 or ESRD.
‡ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart
failure, hypertension, proteinuria, and eGFR <45 mL/min/1.73 m2 or ESRD.23
§CHA2DS2-VASc score includes congestive heart failure; hypertension; age; diabetes
mellitus; stroke, transient ischemic attack, or thromboembolism; vascular disease; and
sex.22
Table 2. Distribution of TTR1 (Months 4–9) for 2841 New
Warfarin Users*
TTR1 Category n (%)
≥70% 1156 (40.7)
65–69% 225 (7.9)
60–64% 213 (7.5)
50–59% 410 (14.4)
<50% 837 (29.5)
TTR1 indicates time in the therapeutic range during the ﬁrst 6-month period.
*Months 4–9 are the ﬁrst 6-month period after the initial 3-month period to establish a
stable warfarin dose.
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clinical inpatient and ambulatory visit, administrative, and
pharmacy databases for the 5 years before each patient’s
cohort index date. Diabetes mellitus was identiﬁed using a
validated diabetes registry.18 Ascertainment of individual
stroke risk factors was validated against a review of samples
of outpatient medical records; crude agreement was high (78–
96%), and corresponding j statistics ranged from 0.51 to
0.89.21
Statistical Analysis
TTR was ﬁrst assessed as a continuous variable, summarized
using mean with standard deviation and median with
interquartile range (quartiles 1–3). We dichotomized TTR at
70%. We assessed patient features correlated with TTR1.
Among those patients with an initial TTR ≥70%, we recorded
the distribution of TTR values in the second 6-month period
(TTR2). We assessed the univariate and multivariable associ-
ations of clinical features with persistence of TTR ≥70% and
with marked deterioration of TTR (ie, TTR <50%). In sensitivity
analyses, we included patients with TTR1 ≥70% who discon-
tinued warfarin in the second 6-month period as part of a
Table 3. Association of Patient Baseline Features With TTR
≥70% in Period 1
Variable* n
Patients With
TTR ≥70% in
Months 4–9, n (%) P Value†
All 2841 1156 (40.7)
Age 0.45
<75 y 1614 647 (40.1)
≥75 y 1227 509 (41.5)
Sex 0.99
Men 1597 650 (40.7)
Women 1244 506 (40.7)
Race 0.44
White 2478 1015 (41.0)
Other 363 141 (38.8)
Diabetes mellitus 0.27
No 2375 977 (41.1)
Yes 466 179 (38.4)
Hypertension 0.65
No 1266 521 (41.2)
Yes 1575 635 (40.3)
Coronary artery disease 0.43
No 2044 841 (41.1)
Yes 797 315 (39.5)
Heart failure 0.14
No 2089 867 (41.5)
Yes 752 289 (38.4)
Peripheral artery disease 0.45
No 2770 1124 (40.6)
Yes 71 32 (45.1)
Renal impairment‡ 0.016
No 2490 1034 (41.5)
Yes 351 122 (34.8)
Prior stroke 0.96
No 2579 1049 (40.7)
Yes 262 107 (40.8)
Cancer 0.35
No 2504 1011 (40.4)
Yes 337 145 (43.0)
Prior bleed 0.34
No 2687 1099 (40.9)
Yes 154 57 (37.0)
Beta blockers 0.057
No 1896 748 (39.5)
Yes 945 408 (43.2)
Continued
Table 3. Continued
Variable* n
Patients With
TTR ≥70% in
Months 4–9, n (%) P Value†
Antiarrhythmics 0.82
No 2372 963 (40.6)
Yes 469 193 (41.2)
Calcium channel blockers 0.15
No 2097 870 (41.5)
Yes 744 286 (38.4)
ATRIA score at admission§ 0.76
0 to 5 1455 601 (41.3)
6 404 164 (40.6)
≥7 982 391 (39.8)
CHA2DS2-VASc score
at admissionk
0.79
0 161 66 (41.0)
1 439 185 (42.1)
≥2 2241 905 (40.4)
ATRIA indicates anticoagulation and risk factors in atrial ﬁbrillation; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease; TTR, time in the therapeutic
range.
*Variables assessed at the beginning of the 15-month follow-up period.
†P values from chi-square tests.
‡eGFR <45 mL/min/1.73 m2 or ESRD.
§ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart
failure, hypertension, proteinuria, and eGFR <45 mL/min/1.73 m2 or ESRD.23
kCHA2DS2-VASc score includes congestive heart failure; hypertension; age; diabetes
mellitus; stroke, transient ischemic attack, or thromboembolism; vascular disease; and
sex.22
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composite outcome of deterioration (ie, TTR <50% or discon-
tinued warfarin). We did not include the following categories
of patients in the analysis of TTR2: (1) patients who died in the
second period (n=16); (2) patients who discontinued warfarin
in period 2 but who restarted warfarin >1 year later (n=42);
(3) patients for whom the study follow-up ended before their
second period was complete (n=33); (4) patients who had no
interpolatable INR values in period 2 (n=17); and (5) patients
who ended their health plan membership during period 2
(n=3). Statistical signiﬁcance of univariate associations was
assessed via chi-square tests. Features with a univariate
association of P≤0.20 were entered into logistic regression
models. In these models, P≤0.05 was considered statistically
signiﬁcant.
All analyses were conducted using SAS statistical software,
version 9.4 (SAS Institute Inc).
Results
Of the 13 559 patients in the ATRIA cohort, 4460 met the
criteria for new starts on warfarin during the study period. Of
these, 2928 had ≥9 months of continuous warfarin use,
including our initial 3-month dose-ﬁnding period and our ﬁrst
period assessing TTR (months 4–9). There were 2841 patients
who had interpolatable INR values (ie, calculable TTR values)
in period 1 (Figure 1). Of those, 43% were aged ≥75 years at
baseline, 56% were men, 87% were white, 16% had diabetes
mellitus, 55% had hypertension, 28% had coronary artery
disease, 27% had heart failure, and 12% had diminished renal
function (estimated glomerular ﬁltration rate <45 mL/min per
1.73 m2), among other features. Moreover, 79% had a
CHA2DS2-VASc score
22 ≥2, and 49% had an ATRIA stroke
risk score23 ≥6 (Table 1).
For these 2841 new and continuous warfarin users, the
mean TTR1 was 61.7% (SD 24.2%) and the median was 64.1%
(interquartile range 45.7–80.1%). In total, 1156 (40.7%)
achieved TTR1 ≥70% in the initial period, whereas 29.5%
demonstrated poor control (TTR1 <50%) (Table 2). Most
patient features were unrelated to initial TTR ≥70%, although
patients with renal impairment had statistically signiﬁcantly
lower TTR1, and patients taking beta blockers had borderline
signiﬁcantly higher TTR1 (Table 3). In a multivariable logistic
model, impaired renal function was the sole signiﬁcant
correlate of TTR1, with an adjusted odds ratio of 0.77 (95%
CI 0.61–0.98) for TTR1 ≥70%.
Among the 987 patients who achieved TTR1 ≥70% and had
interpolatable INR values through period 2 (months 10–15),
562 (56.9%) persisted as well-controlled warfarin users (TTR2
≥70%). Most INR time that was out of range was below INR
2.0, and this pattern worsened in lower TTR categories
(Figure 2). Expanding the deﬁnition of good-quality TTR2 to
≥65%, 650 (65.9%) persisted as good-quality warfarin users
(TTR2 ≥65%). If the target INR range was expanded to include
the full optimal INR range of 1.8 to 3.5 in the subsequent
period, 891 (90.3%) achieved a TTR2 ≥70%.
In univariate analyses, TTR (using INR 2.0–3.0, the
standard therapeutic range) in the initial period, absence of
renal impairment, and absence of heart failure were signiﬁ-
cantly associated with high-quality TTR in the subsequent
period (Table 4). In multivariable analysis, only TTR1 ≥90%
remained a strong independent predictor of persistent high-
quality warfarin therapy (adjusted odds ratio 1.47, 95% CI
1.07–2.01) (Table 4).
Among patients with TTR1 ≥70%, 154 (15.6%) had the poor
outcome of a TTR2 <50% (Figure 2). Only heart failure was
signiﬁcantly associated with deterioration to TTR <50% in the
subsequent period (adjusted odds ratio 1.45, 95% CI 1.00–
2.10) (Table 5). Of 1045 patients achieving a TTR ≥70% in
months 4 to 9, 58 discontinued warfarin in months 10 to 15.
If we broadened our deﬁnition of poor outcome to the
composite of TTR2 <50% or discontinued warfarin, no patient
features were signiﬁcantly related to poor outcome in
multivariable models. With this expanded deﬁnition of poor
outcome, the adjusted odds ratio for heart failure was 1.24
(95% CI 0.89–1.73).
Figure 2. The distribution of TTR values in the second 6-month
period (TTR2, months 10–15) among the 987 warfarin-treated
ATRIA atrial ﬁbrillation cohort patients whose TTR in the ﬁrst 6-
month period (TTR1: months 4–9) was ≥70% and who continued
warfarin with a calculable TTR in period 2. An additional 58 patients
had TTR1 ≥70% but discontinued warfarin in period 2. These last
patients are included in a sensitivity analysis. Note that the initial
3 months on warfarin (months 1–3) were excluded because time is
needed to establish warfarin dosing. The mean percentage of time
below INR 2.0 and above INR 3.0, respectively, for the 5 ordered
categories of TTR2 were (1) TTR2 ≥70%: 8.6% and 5.4%; (2) TTR2
65–69%: 20.5% and 12.1%; (3) TTR2 60–64%: 25.5% and 11.6%; (4)
TTR2 50–59%: 29.3% and 15.6%; and (5) TTR2 <50%: 48.6% and
16.6%. ATRIA indicates anticoagulation and risk factors in atrial
ﬁbrillation; TTR, time in the therapeutic range.
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Discussion
Using a large real-world community cohort of AF patients
newly and continuously taking warfarin, we assessed how well
Table 4. Univariate and Multivariable Correlates of TTR ≥70%
in Months 10–15 Among Those With TTR ≥70% in Months 4–9
(n=987)*
Variable† n
Patients With
TTR ≥70%
in Months
10–15, n (%)
Univariate
P Value‡
Multivariable
Odds Ratio
(95% CI)§
All 987 562 (56.9) NA NA
TTR in months 4
–9
0.018
70–79% 375 202 (53.9) Ref
80–89% 319 173 (54.2) 1.03
(0.76–1.39)
≥90% 293 187 (63.8) 1.47
(1.07–2.01)k
Age 0.79
<75 y 511 293 (57.3)
≥75 y 476 269 (56.5)
Sex 0.46
Men 552 320 (58.0)
Women 435 242 (55.6)
Race 0.74
White 874 496 (56.8)
Other 113 66 (58.4)
Diabetes mellitus 0.073 0.80
(0.56–1.13)
No 823 479 (58.2)
Yes 164 83 (50.6)
Hypertension 0.24
No 418 229 (54.8)
Yes 569 333 (58.5)
Coronary heart
disease
0.69
No 717 411 (57.3)
Yes 270 151 (55.9)
Heart failure 0.012 0.79
(0.59–1.06)
No 705 419 (59.4)
Yes 282 143 (50.7)
Peripheral artery
disease
0.34
No 958 548 (57.2)
Yes 29 14 (48.3)
Renal
impairmentk
0.027 0.74
(0.50–1.11)
No 871 507 (58.2)
Yes 116 55 (47.4)
Prior stroke 0.89
Continued
Table 4. Continued
Variable† n
Patients With
TTR ≥70%
in Months
10–15, n (%)
Univariate
P Value‡
Multivariable
Odds Ratio
(95% CI)§
No 895 509 (56.9)
Yes 92 53 (57.6)
Cancer 0.63
No 865 495 (57.2)
Yes 122 67 (54.9)
Prior bleed 0.98
No 938 534 (56.9)
Yes 49 28 (57.1)
Beta blockers 0.65
No 658 378 (57.4)
Yes 329 184 (55.9)
Antiarrhythmics 0.45
No 881 498 (56.5)
Yes 106 64 (60.4)
Calcium channel
blockers
0.31
No 753 422 (56.0)
Yes 234 140 (59.8)
ATRIA score¶ 0.91
0–5 472 272 (57.6)
6 136 77 (56.6)
≥7 379 213 (56.2)
CHA2DS2-VASc
score#
0.069
0 44 25 (56.8) Ref
1 138 91 (65.9) 1.53
(0.76–3.07)
≥2 805 446 (55.4) 1.14
(0.61–2.14)
ATRIA indicates anticoagulation and risk factors in atrial ﬁbrillation; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease; NA, not available; Ref,
reference; TTR, time in the therapeutic range.
*Included patients had to have a calculable TTR in period 2.
†Variables assessed at the start of month 10 of follow-up.
‡Univariate P values from chi-square tests.
§Variables entered into the multivariable logistic model were TTR in months 4–9,
diabetes mellitus, heart failure, and renal impairment.
keGFR <45 mL/min/1.73 m2 or ESRD.
¶ATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart
failure, hypertension, proteinuria, and eGFR <45 mL/min/1.73 m2 or ESRD.23
#CHA2DS2-VASc score includes heart failure; hypertension; age; diabetes mellitus;
stroke, transient ischemic attack, or thromboembolism; vascular disease; and sex.22
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good control of anticoagulation persisted. We allowed an
initial dose-ﬁnding period of months 1 to 3 and then
calculated the TTR in study period 1 (months 4–9). We then
focused on patients with high-quality anticoagulation (ie, TTR
≥70%) in period 1 and followed them over a subsequent
6-month period (months 10–15). We found that 41% of
Table 5. Univariate and Multivariable Correlates of Markedly
Deteriorated TTR (<50%) Among Those With TTR ≥70% in
Months 4–9 (n=987)
Variable* n
Patients With
TTR <50%
in Months
10–15, n (%)
Univariate
P Value†
Multivariable
Odds
Ratio (95% CI)‡
All 987 154 (15.6) NA NA
TTR in months 4
–9
0.66
70–79% 375 54 (14.4)
80–89% 319 54 (16.9)
≥90% 293 46 (15.7)
Age 0.63
<75 y 511 77 (15.1)
≥75 y 476 77 (16.2)
Sex 0.71
Men 552 84 (15.2)
Women 435 70 (16.1)
Race 0.47
White 874 139 (15.9)
Other 113 15 (13.3)
Diabetes mellitus 0.92
No 823 128 (15.6)
Yes 164 26 (15.9)
Hypertension 0.83
No 418 64 (15.3)
Yes 569 90 (15.8)
Coronary heart
disease
0.34
No 717 107 (14.9)
Yes 270 47 (17.4)
Heart failure 0.02 1.45
(1.00–2.10)
No 705 98 (13.9)
Yes 282 56 (19.9)
Peripheral artery
disease
0.43
No 958 151 (15.8)
Yes 29 3 (10.3)
Renal
impairment§
0.18 1.25
(0.75–2.07)
No 871 131 (15.0)
Yes 116 23 (19.8)
Prior stroke 0.68
No 895 141 (15.8)
Yes 92 13 (14.1)
Continued
Table 5. Continued
Variable* n
Patients With
TTR <50%
in Months
10–15, n (%)
Univariate
P Value†
Multivariable
Odds
Ratio (95% CI)‡
Cancer 0.43
No 865 132 (15.3)
Yes 122 22 (18.0)
Prior bleed 0.29
No 938 149 (15.9)
Yes 49 5 (10.2)
Beta blockers 0.62
No 658 100 (15.2)
Yes 329 54 (16.4)
Antiarrhythmics 0.064 0.52
(0.27–1.03)
No 881 144 (16.3)
Yes 106 10 (9.4)
Calcium channel
blockers
0.12 0.72
(0.46–1.11)
No 753 125 (16.6)
Yes 234 29 (12.4)
ATRIA score at
admissionk
0.33
0–5 472 73 (15.5)
6 136 16 (11.8)
≥7 379 65 (17.2)
CHA2DS2-VASc
score at
admission¶
0.57
0 44 5 (11.4)
1 138 19 (13.8)
≥2 805 130 (16.1)
ATRIA indicates anticoagulation and risk factors in atrial ﬁbrillation; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease; NA, not available; TTR, time in
the therapeutic range.
*Variables assessed at the start of month 10 of follow-up.
†Univariate P values from chi-square tests.
‡Variables entered into the multivariable logistic model were heart failure, renal
impairment, antiarrhythmics, and calcium channel blockers at the start of month 10.
§eGFR <45 mL/min/1.73 m2 or ESRD.
kATRIA risk score includes prior stroke, age, sex, diabetes mellitus, congestive heart
failure, hypertension, proteinuria, and eGFR <45 mL/min/1.73 m2 or ESRD.23
¶CHA2DS2-VASc score includes heart failure; hypertension; age; diabetes mellitus;
stroke, transient ischemic attack, or thromboembolism; vascular disease; and sex.22
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patients achieved TTR ≥70% in period 1. Of these, 57%
persisted at TTR ≥70% in period 2. Another 8.9% maintained a
TTR2 between 65% and 69%, a range still considered good
quality and better than levels seen in recent randomized
trials.24 With the target INR range in period 2 deﬁned as 1.8 to
3.5, fully 90% maintained TTR ≥70%. Empirical evidence shows
that the optimal INR range for AF is 1.8 to 3.5, not just 2.0 to
3.0.7 Only 16% deteriorated to a TTR <50% (using the
standard target of INR 2.0–3.0). Although excellent TTR (ie,
≥90%) predicted continued high TTR levels, no other clinical
feature was signiﬁcantly associated with TTR ≥70% in the
second period of warfarin anticoagulation. The presence of
heart failure was the only signiﬁcant predictor of marked
deterioration (ie, TTR <50%) in the second follow-up period.
When we expanded our deﬁnition of poor outcome in period 2
to include both TTR <50% or discontinuing warfarin, no clinical
feature was signiﬁcantly and independently associated with
poor outcome. Our results indicate that most patients with
well-controlled warfarin therapy continue to do well.
Because INR levels between 2.0 and 3.0 are associated with
low rates of both ischemic stroke and major bleeding, linearly
interpolated TTR has become a standard measure of quality of
warfarin management.11 Several clinical trials have provided
evidence of warfarin’s improved efﬁcacy at high TTR levels,
usually deﬁned as approximately ≥70%.12,14,25 Multiple studies
have aimed to identify predictors of TTR, including language,
race, sex, age, and medical history, but such patient features
account for only a small fraction of the variance of TTR.26–29 We
found that only impaired renal function was signiﬁcantly and
inversely associated with TTR ≥70% in our ﬁrst period of follow-
up (months 4–9). Patients with impaired renal function were
largely excluded from the trials of novel anticoagulants. These
recently developed anticoagulants are not optimal replace-
ments for warfarin in the face of renal insufﬁciency.24,30–32
AF patients receiving warfarin now have the opportunity to
switch to novel oral anticoagulants. These agents have
comparable efﬁcacy for reducing risk of stroke and do not
require frequent INR monitoring. They have a clear advantage
in reducing rates of intracranial hemorrhage compared with
warfarin by approximately four per thousand per year.33
Although there is some inconsistency across trials,34 warfarin
at TTR ≥70% appears to be equivalent to novel anticoagulants
in terms of preventing stroke and systemic embolism, with
increased risk of hemorrhagic stroke countered by reduced
risk of ischemic stroke.12,14 There may still be a small beneﬁt
favoring novel agents in terms of nonstroke intracranial
hemorrhage, partially balanced by an increased risk of
gastrointestinal hemorrhage.33 Patients are likely to incur
greater out-of-pocket costs with novel agents than with
warfarin.35 Moreover, patients may prefer to continue taking
warfarin.36 Our results are directly relevant to patients
deciding whether to continue warfarin or to seek a substitute
and for whom the convenience of novel agents is not an
important factor. Our results support a watchful waiting
approach for AF patients who have achieved a TTR ≥70% when
taking warfarin because most of these patients will continue
to do well. Providers should be particularly attentive to
patients with heart failure because such patients are at
modestly increased risk of substantial deterioration in TTR.37
Our study represents the experience of AF patients in a
community-based cohort within a large, well-resourced, inte-
grated health care delivery system. Management of warfarin
was coordinated predominantly through dedicated anticoagu-
lation management services. Our results should apply broadly
to patients whose anticoagulation was managed in a similar
fashion. It is not clear whether our ﬁndings generalize to other,
less formal systems of managing anticoagulation. High-quality
warfarin anticoagulation depends on patients obtaining fre-
quent INR tests. Patient- or system-level barriers to such a
testing regimen will pose a challenge to maintaining TTR levels
≥70%. Our results strictly apply to AF patients at the 9-month
mark after initiating warfarin therapy. Although we assume
these results apply more broadly to all AF patients after a
prolonged period (ie, 6 months) of high-quality warfarin
treatment, validation of this assumption awaits further study.
Conclusion
Overall, 57% of AF patients with high-quality 6-month TTR
after initiating warfarin (excluding an initial 3-month dose-
ﬁnding period) maintained TTR ≥70% over the subsequent
6 months. A minority deteriorated to very poor TTR. Patient
features do not strongly predict deterioration, although heart
failure moderately increases this risk. Our analyses support
watchful waiting for AF patients with initial high-quality
warfarin anticoagulation before considering switching to a
novel anticoagulant.
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SUPPLEMENTAL MATERIAL 
 
Table S1. Characteristics of patients with and without 9 months of continuous warfarin use 
following initial prescription 
 
 
Patients with at least 
9 months of 
continuous warfarin 
use 
Patients without 9 
months of 
continuous warfarin 
use  
Variable* N (%) N (%) P value† 
All 2928 (100%) 1532 (100%)  
Age   0.60 
   ≥75 years 1264 (43.2%) 656 (42.8%)  
Sex   0.022 
   Women 1272 (43.4%) 611 (39.9%)  
Race   0.002 
   White 2555 (87.3%) 1291 (84.3%)  
Diabetes mellitus   0.87 
   Yes 480 (16.4%) 254 (16.6%)  
Hypertension   0.089 
   Yes 1611 (55.0%) 802 (52.3%)  
Coronary artery disease   0.60 
   Yes 813 (27.8%) 414 (27.0%)  
Heart failure   0.79 
   Yes 779 (26.6%) 402 (26.2%)  
Peripheral artery disease   0.62 
   Yes 74 (2.5%) 35 (2.3%)  
Renal impairment‡   0.72 
 Patients with at least 
9 months of 
continuous warfarin 
use 
Patients without 9 
months of 
continuous warfarin 
use  
Variable* N (%) N (%) P value† 
   Yes 360 (12.3%) 194 (12.7%)  
Prior stroke   0.020 
   Yes 279 (9.5%) 114 (7.4%)  
Cancer   0.012 
   Yes 342 (11.7%) 219 (14.3%)  
Prior bleed   0.019 
   Yes 162 (5.5%) 112 (7.3%)  
Beta blockers   0.79 
   Yes 969 (33.1%) 513 (33.5%)  
Anti-arrhythmics   0.073 
   Yes 484 (16.5%) 286 (18.7%)  
Calcium channel blockers   0.68 
   Yes 764 (26.1%) 391 (25.5%)  
ATRIA score at admission§   0.18 
   0-5 1500 (51.2%) 824 (53.8%)  
   6 418 (14.3%) 200 (13.1%)  
   ≥7 1010 (34.5%) 508 (33.2%)  
CHA2DS2-VASc score at 
admission|| 
  0.001 
   0 168 (5.7%) 134 (8.7%)  
 Patients with at least 
9 months of 
continuous warfarin 
use 
Patients without 9 
months of 
continuous warfarin 
use  
Variable* N (%) N (%) P value† 
   1 457 (15.6%) 265 (17.3%)  
   ≥2 2303 (78.7%) 1133 (74.0%)  
*Variables assessed at the beginning of the 15-month follow-up period.
 
†
Univariate p values from chi-square tests.  
‡
 Estimated glomerular filtration rate <45 ml/min/1.73m
2 
or end stage renal disease.  
§
 ATRIA risk score includes prior stroke, age, sex, diabetes, congestive heart failure, hypertension, proteinuria, and eGFR<45 or 
ESRD.
36 
||
CHA2DS2VASc score includes congestive heart failure, hypertension, age, diabetes mellitus, stroke/TIA/thromboembolism, vascular 
disease, and sex.
37
  
 
